BioTime (BTX)'s Subsidiary OncoCyte Corporation Provides Update on PanC-DxTM, and Related Diagnostic Products
4/24/2012 8:42:13 AM
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex: BTX) announced today that Joseph Wagner, Ph.D., the CEO of BioTime’s subsidiary OncoCyte Corporation and Karen B. Chapman, Ph.D., Director of Bioinformatics will provide updates on the development of the Company’s pan-cancer diagnostic PanC-DxTM and related diagnostics at an investor meeting in New York City. PanC-DxTM is a screening diagnostic that may permit the use of a blood test to screen patients for a number of solid cancer types such as those of the breast, colon, and lung. In his presentation, Dr. Wagner will describe the next-generation cancer diagnostics based on improved technologies in genomics and proteomics. He will also update investors on the planned development timeline of PanC-DxTM leading to an anticipated product launch in Europe in late 2014.
comments powered by